Misfeldt Dayton 4
4 · SUNESIS PHARMACEUTICALS INC · Filed Oct 30, 2017
Insider Transaction Report
Form 4
Misfeldt Dayton
Director10% Owner
Transactions
- Purchase
Common Stock
2017-10-27$2.00/sh+7,480$14,960→ 30,456 total(indirect: See footnotes.) - Purchase
Common Stock Warrants (right to buy)
2017-10-27+196,260→ 196,260 total(indirect: See footnotes.)Exercise: $3.00From: 2017-10-27Exp: 2018-10-27→ Common Stock (196,260 underlying) - Purchase
Common Stock
2017-10-27$2.00/sh+392,520$785,040→ 1,598,260 total(indirect: See footnotes.) - Purchase
Common Stock Warrants (right to buy)
2017-10-27+3,740→ 3,740 total(indirect: See footnotes.)Exercise: $3.00From: 2017-10-27Exp: 2018-10-27→ Common Stock (3,740 underlying)
Holdings
- 252(indirect: See footnotes.)
Common Stock
Footnotes (6)
- [F1]The reporting person is a Managing Director of Bay City Capital LLC, a Delaware limited liability company ("BCC"). BCC is the manager of Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"). Management V is the general partner of Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V") and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V") and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held. Mr. Misfeldt, BCC and Management V disclaim beneficial ownership with respect to the securities reported in this Form 4, except to the extent of their pecuniary interest therein.
- [F2]The securities are held by Fund V.
- [F3]The securities are held by Co-Investment V.
- [F4]The securities are held by BCC.
- [F5]The reported securities are included within the 392,520 shares of common stock and accompanying warrants purchased by the reporting person. The per share price of $2.00 includes one share of common stock and the accompanying warrant to purchase 0.5 share of common stock.
- [F6]The reported securities are included within the 7,480 shares of common stock purchased by the reporting person. The per share price of $2.00 includes one share of common stock and the accompanying warrant to purchase 0.5 share of common stock.